



Gene Set Analysis – Methods and Tools

Antonio Mora, Ph.D.

(Wechat: antoniocmora) www.moralab.science

21.09.2020







18.18.23

Learn how to distribute your work using this licence





Contents

- 2.1. What is Gene Set Analysis.
- 2.2. Before starting a Gene Set Analysis.
- 2.3. Gene Set Analysis --ORA
- 2.4. Gene Set Analysis FCS
- 2.5. Multiple testing correction
- 2.6. Gene Set Analysis --Software





Contents

2.1. What is Gene Set Analysis.

2.2. Before starting a Gene Set Analysis
2.3. Gene Set Analysis --ORA
2.4. Gene Set Analysis –FCS
2.5. Multiple testing correction
2.6. Gene Set Analysis --Software



You may have heard about:

- Pathway (enrichment) Analysis
- Gene Set (enrichment) Analysis
- Functional Enrichment Analysis
- Ontology Analysis
- Knowledge-driven pathway analysis
- And other names...

It is all the same. We are at the end of a research project and we want to find the meaning of the group of biological molecules that we obtained as a result. What is interesting about them? How are they related to each other?



http://bioinfo.vanderbilt.edu/vangard/services-rnaseq.html



MYC



https://www.otogenetics.com/wp-content/uploads/2017/12/RNA-Seq-VS-Microarray.jpg https://www.researchgate.net/figure/ChIP-seq-workflow-and-dataanalysis_fig1_321662815









Gene set analysis: Interpreting the query set as pathways or other gene sets.



"Gene Set Analysis" Elements:

A query set: A group of genes that were the result of some experiment *Example of query set:* Differentially expressed genes (up-regulated, downregulated, or the entire list).

| HK1 |
|--------|
| ADPGK |
| GPI |
| PGK1 |
| PKM2 |
| ALDOA |
| GAPDH |
| BPGM |
| ENO1 |
| PFKP |
| GRB2 |
| HRAS |
| PI3K |
| RAC1 |
| PAK1 |
| MEKK1 |
| MEKK2 |
| ERK1 |
| CREBBP |
| MYC |
| |

Reference Databases:

Pathway / Ontology / Gene set Databases.







Statistical Method

Is my group of genes more enriched in one specific gene set than a group of genes randomly chosen?



Gene Set Analysis Workflow

¥.

COMPUTATIONAL METHODS



https://doi.org/10.1093/bib/bbz090

自自自由

REFERENCE DATABASES

10.15





Statistical Tests





The ORA approach (For a gene list, e.g. genes with expression change > 2-fold)

Pathway A:



Pathway A is enriched with genes from my gene list





Pathway B:



Pathway C:



Pathway B is not enriched with genes from my gene list



G7

My Gene List:

Question: Is Pathway C surprisingly enriched with genes from my gene list? My Gene List:





The ORA approach (For a gene list, e.g. genes with expression change > 2-fold)

Over-representation analysis (ORA) is the task of identifying the pathways that contain a number of genes from our gene list that would be hard to find by chance alone.



Are the genes in the intersection too many? What do we mean when we say "too many"? 5 out of 10? 7 out of 10? (We must use Statistics and compare to how many we can find by chance alone!)



The ORA approach (For a gene list, e.g. genes with expression change > 2-fold)



<u>Statistical test</u>: Are there more genes in the intersection than expected by chance alone? (p-value < 0.05?)

Adapted from: Canadian Bioinformatics Workshop



Usually, we do this for all gene sets in the database, and build a table





The FCS approach (Gene rank, e.g. entire list, ordered by differential expression)





Usually, we do this for all gene sets in the database, and build a table







Contents

2.1. What is Gene Set Analysis.

2.2. Before starting a Gene Set Analysis.

2.3. Gene Set Analysis --ORA
2.4. Gene Set Analysis –FCS
2.5. Multiple testing correction
2.6. Gene Set Analysis --Software







The Gene / Protein List

- Be careful about gene/protein identifiers.
- Identifiers (IDs) are ideally unique, stable names or numbers that help track database records. For example, your wechat ID, Entrez Gene ID 41232, etc
- Gene and protein information stored in many databases
 - \rightarrow Genes have many IDs
- Records for: Gene, DNA, RNA, Protein
 - Important to recognize the correct record type

We need both the query set and the pathways/gene sets using the same type of identifiers

HK1 ADPGK GPI PGK1 PKM2 ALDOA GAPDH BPGM ENO1 PFKP GRB2 HRAS PI3K RAC1 PAK1 MEKK1 MEKK2 ERK1 CREBBP MYC



Common Identifiers

Gene Ensembl ENSG00000139618 Entrez Gene 675

Unigene Hs.34012

RNA transcript GenBank BC026160.1 RefSeq NM_000059 Ensembl ENST00000380152

Protein

Ensembl ENSP00000369497 <u>RefSeq</u> NP_000050.2 <u>UniProt</u> BRCA2_HUMAN or A1YBP1_HUMAN IPI IPI00412408.1 EMBL AF309413 PDB 1MIU **Species-specific**

HUGO HGNC BRCA2 MGI MGI:109337 RGD 2219 **ZFIN ZDB-GENE-060510-3** FlyBase CG9097 WormBase WBGene00002299 or ZK1067.1 SGD S00002187 or YDL029W Annotations InterPro IPR015252 OMIM 600185 Pfam **PF09104** Gene Ontology GO:0000724 SNPs rs28897757 **Experimental Platform** Affymetrix 208368_3p_s_at Agilent A_23_P99452 Red =CodeLink GE60169 Recommended Illumina GI_4502450-S



Identifier Mapping

- So many IDs!
 - Software tools recognize only a handful
 - May need to map from your gene list IDs to standard IDs
- Four main uses
 - Searching for a favorite gene name
 - Link to related resources
 - Identifier translation
 - E.g. Proteins to genes, Affy ID to Entrez Gene
 - Merging data from different sources
 - Find equivalent records



ID Mapping Services



¥.

| | >> Static URL Come back later | | | | | | | |
|----|--|-----|--|---|--|--|--|--|
| g# | initial alias >> g:GOSt >> g:Sorter >> g:Orth >> g:Cocoa | c# | converted alias >> g:GOSt >> g:Sorter >> g:Orth >> g:Cocoa >> Copy values | name >> g:GOSt >> g:Sorter >> g:Orth >> g:Cocoa >> Copy values | description | namespace | | |
| 1 | ТР53 | 1.1 | P04637 | ТР53 | tumor protein p53 [Source:HGNC Symbol;Acc:HGNC:11998] | UNIPROT_GN, ENTREZGENE, VEGA_GENE, DBASS5, DBASS3, HGNC, WIKIGENE | | |
| 2 | MDM2 | 2.1 | Q00987 | MDM2 | MDM2 proto-oncogene, E3 ubiquitin protein ligase [Source:HGNC Symbol;Acc:HGNC:6973] | UNIPROT_GN, ENTREZGENE, VEGA_GENE, HGNC, WIKIGENE | | |
| 3 | 207105_S_AT | 3.1 | 000459 | PIK3R2 | phosphoinositide-3-kinase, regulatory subunit 2 (beta) [Source:HGNC Symbol;Acc:HGNC:8980] | AFFY_HG_U133_PLUS_2, AFFY_HG_FOCUS, AFFY_HG_U133A_2, AFFY_HG_U133A | | |
| 4 | P60484 | 4.1 | P60484 | PTEN | phosphatase and tensin homolog [Source:HGNC Symbol;Acc:HGNC:9588] | UNIPROTSWISSPROT | | |

- g:Convert
- http://biit.cs.ut.ee/gprofiler/gconvert.cgi

Ensembl Biomart

http://www.ensembl.org

. AFFY HG U95C AFFY_HG_U95D AFFY HG U95E AFFY_HTA_2_0 AFFY HUEX 1 0 ST V2 AFFY_HUGENEFL AFFY HUGENE 1 0 ST V1 AFFY_HUGENE_2_0_ST_V1 AFEY PRIMEVIEW AFEY U133 X3P AGILENT_CGH_44B AGILENT SUREPRINT G3 GE 8X60K AGILENT_SUREPRINT_G3_GE_8X60K_V2 AGILENT_WHOLEGENOME_4X44K_V1 AGILENT_WHOLEGENOME_4X44K_V2 ARRAYEXPRESS CCDS CCDS_ACC CHEMBL CLONE_BASED_ENSEMBL_TRANSCRIPT CLONE_BASED_VEGA_GENE CLONE_BASED_VEGA_TRANSCRIPT CODELINK CODELINK DBASS3 DBASS3_ACC DBASS5 DBASS5_ACC EMBL ENSG ENSP ENST ENS_HS_TRANSCRIPT ENS_HS_TRANSLATION ENS_LRG_GENE ENS_LRG_TRANSCRIPT ENTREZGENE ENTREZGENE ACC ENTREZGENE_TRANS_NAME GO GOSLIM_GOA HGNC HGNC_ACC HGNC_TRANS_NAME HPA HPA_ACC ILLUMINA_HUMANHT_12_V3 ILLUMINA HUMANHT 12 V4 ILLUMINA_HUMANREF_8_V3 ILLUMINA HUMANWG 6 V1 ILLUMINA_HUMANWG_6_V2 ILLUMINA_HUMANWG_6_V3 MEROPS MIM_GENE MIM_GENE_ACC MIM MORBID MIM MORBID ACC MIRBASE MIRBASE_ACC MIRBASE TRANS NAME OTTG OTTP OTTT PDB PHALANX_ONEARRAY PROTEIN_ID PROTEIN_ID_ACC REFSEQ_MRNA REFSEQ MRNA ACC REFSEO MRNA PREDICTED REFSEQ_MRNA_PREDICTED_ACC •





ID Challenges

- Avoid errors: map IDs correctly
 - Beware of 1-to-many mappings
- Gene name ambiguity not a good ID
 - e.g. FLJ92943, LFS1, TRP53, p53
 - Better to use the standard gene symbol: TP53
- Excel error-introduction
 - OCT4 is changed to October-4 (paste as text)
- Problems reaching 100% coverage
 - E.g. due to version issues
 - Use multiple sources to increase coverage

Zeeberg BR et al. Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics BMC Bioinformatics. 2004 Jun 23;5:80





Contents

2.1. What is Gene Set Analysis.
2.2. Before starting a Gene Set Analysis
2.3. Gene Set Analysis --ORA
2.4. Gene Set Analysis --FCS
2.5. Multiple testing correction
2.6. Gene Set Analysis --Software





Gene List





Statistical (Enrichment) Test:

What do you mean "enriched"? How many genes are "too many"?

The statistical formulation: If we randomly choose "n" genes, how likely is that all the "n" genes will be in a certain pathway?

If it is very unlikely (low probability), we say that the sample genes are over-represented in that pathway. PIC:

Low probability = Difficult by chance = Gene set may represent gene list

High probability = Easy by chance = Gene set don't represent gene list





The most common ORA test is using the "Hypergeometric distribution" (HG).

N = Population



The HG describes the probability (P) of k successes in n draws, without replacement, from a population of size N that contains K successes.

The Statistical Test: Is this more enriched than expected by chance alone? Is it better than P?

N = Number of items in the population

K = Number of items in the population that we call "successes"

n = Number of items in the sample

k = Number of successes in the sample

Question: What is the probability of success P?





Probability of success: P(X=k)

$$P(X=k)=rac{\binom{K}{k}\binom{N-K}{n-k}}{\binom{N}{n}}$$
 ,

$$egin{pmatrix} n \ k \end{pmatrix} = rac{n!}{k!\,(n-k)!} \quad ext{for} \ \ 0 \leq k \leq n,$$

$$egin{aligned} n! &= \prod_{k=1}^n k \ &= 1 \cdot 2 \cdot 3 \cdots (n-2) \cdot (n-1) \cdot n \ &= n(n-1)(n-2) \cdots (2)(1) \end{aligned}$$

$$4! = 4 * 3 * 2 * 1$$



Example: Suppose we randomly select 5 cards without replacement from a deck of cards. What is the probability of getting exactly 2 red cards?



() 荐 111 端 科 久 身 GUANGZHOU MEDICAL UNIVERSITY **Example:** We have 52 students, 26 tall and 26 small. Suppose we randomly select 5 students from the group. What is the probability of getting exactly 2 tall students?

N = Population = Allstudents = 52K = Population success = All tall students = 26n = Sample = 5k = Sample success = Tall students in the sample = 2 N - K = 26n - k = 3What is the probability of success?

Probability of success: P(X=k)

$$P(X = 2) = \frac{\binom{26}{2}\binom{26}{3}}{\binom{52}{5}}$$

$$P(X=2) = \frac{325 * 2600}{2598960} = 0.3251$$



Example: Suppose we are using a database with 52 genes distributed in two pathways, each having 26 genes. Suppose we found 5 differentially-expressed genes in our experiment. What is the probability of getting exactly 2 genes in pathway A?

N = Population = Allgenes in the database = 52 K = Population success = All genes in pathway A = 26 n = Sample = Our full setof DEG = 5k = Sample success = 2N - K = 26n - k = 3

唐州影科大学

GUANGZHOU MEDICAL UNIVERSITY

Probability of success: P(X=k)

$$P(X=2) = \frac{\binom{26}{2}\binom{26}{3}}{\binom{52}{5}}$$

$$P(X=2) = \frac{325 * 2600}{2598960} = 0.3251$$



- But our original question was not the probability of success. The question was if the genes are enriched (over-represented) in that pathway or not.
- We usually accept a threshold of p = 0.05 to decide that.
- Our p = 0.3251 is much higher than that, which means that is easy for those two genes to appear in pathway A just by chance. Therefore, we say that those two genes are not enriched in pathway A.





- ORA tools search for over-representation in a given database of pathways.
- In each case, the sample success is the intersection between our list of genes and one specific pathway (f.ex., if there are 3 genes of our list in pathway B, k=3 for pathway B).
- The tool shows as results the pathways with p smaller than our threshold (usually, 0.05).



The Background

Need to choose "background population" appropriately, e.g., if only portion of the total gene complement is queried (or available for annotation), only use that population as background.



Adapted from: Canadian Bioinformatics Workshop



Should we analyze all genes together? Or separate analyses for up-regulated and down-regulated?

five types of tumours, we illustrate that the separate analysis of up- and downregulated genes could identify more pathways that are really pertinent to phenotypic difference. In conclusion, analysing up- and downregulated genes separately is more powerful than analysing all of the DE genes together.




Should we use all genes in a pathway or gene set?

Some authors filter the gene sets:

Remove gene sets with only a few genes and those with a very large number of genes. Some authors prefer to divide large pathways into sub-pathways:

Low et al. [67] divided the estrogen metabolic pathway into three subpathways involved in androgen synthesis, androgen-to-estrogen conversion and estrogen removal and then found only SNPs within the androgen-to-estrogen conversion pathway were significantly associated with breast and endometrial cancer susceptibilities.





Contents

2.1. What is Gene Set Analysis.
2.2. Before starting a Gene Set Analysis
2.3. Gene Set Analysis --ORA
2.4. Gene Set Analysis --FCS
2.5. Multiple testing correction
2.6. Gene Set Analysis --Software



Problems with gene lists

- Threshold for up- and down-regulated genes is arbitrary (f.ex., fold-change > 2, or log-fold-change > 1.5)
- We get different results at different threshold settings.
- Changes in pathway activity can happen not only if we have a few highly differentially expressed genes but also if we have multiple genes more modestly differentially expressed.





Functional Class Scoring (FCS)





How to score a gene set?



Where are the gene-set genes located in the ranked list? Is there distribution random, or is there an enrichment in either end?

Eden E, Lipson D, Yogev S, Yakhini Z. Discovering motifs in ranked lists of DNA sequences. PLoS Comput Biol. 2007 Mar 23;3(3):e39



How to score a gene set?



| | G9 G5 G7 G2 G3 G4 |
|------|----------------------------------|
| | G6 G8 |
| | G10 |
| | G11 G15 |
| | G33 G20 |
| | G21 G25 |
| | |

My Gene Rank

CO

Scoring a gene set using the mean rank:

| Gene Set 2 |
|-----------------------------|
| |
| |
| |
| |
| |
| |
| Mean Rank = (4+5+6+7+10) |
| (4+3+6+7+10) / 5 = 6.4 |
| |

There are more complex scoring methods, such as: KS, max-mean, and others



GSEA/mHG: Method



Every present gene (thick red vertical bar) gives a positive contribution, Every absent gene (black vertical bar) gives a negative contribution

Warning: the alignment here between bars and plot is a little off

For mHG, ES score = -log P of hypergeometric test at that threshold



GSEA/mHG: Method



1. Maximum (or minimum) ES score is the final **ES score** for the gene set

2. Can define "leading edge subset" as all those genes ranked as least as high as the enriched set.



Going from ES score to p-value

We can compute an empirical p-value using permutations, in the following way:

- 1. Transforming the gene rank into "n" random ranks and then applying the previous procedure in each case. In the end, we will end up with "n" ES values from the random cases.
- 2. Then we will compare our real ES value to all the "n" random ones. Ideally, our ES value should be higher than the random ones, but it is possible to get some cases where it is smaller just by chance. The ratio of times that a random ES is better than the real one, is our p-value. 5 successes of the random ES out of 100 trials would mean a p-value of 0.05.



In statistical terms...

Empirical p-value estimation (for every geneset)

1. Generate null-hypothesis distribution from randomized data





In statistical terms...

Estimate empirical p-value by comparing observed max ES score to null-hypothesis distribution from randomized data (for every gene-set)







Contents

2.1. What is Gene Set Analysis.
2.2. Before starting a Gene Set Analysis.
2.3. Gene Set Analysis --ORA
2.4. Gene Set Analysis --FCS
2.5. Multiple testing correction
2.6. Gene Set Analysis --Software



Multiple testing correction

A p<0.05 means that there is still a 5% probability of finding some correlation purely by chance. This is a small number, but if you play it 1000 times, it gets very probable that you will find a positive result just by chance.

Therefore, a *correction for multiple testing* is needed. Some of the methods include *Bonferroni* and *False Discovery Rate (FDR)*.



Simple P-value correction: Bonferroni

* If M = # Tests:

Corrected p-value = M * original p-value

- In other words, we are looking for p<0.05/M. If M is 1000 tests (1000 pathways, f.ex.), now p must be less than 0.00005
- Bonferroni correction is very stringent and can "wash away" real enrichments leading to false negatives



False discovery rate (FDR)

- FDR is the expected **proportion** of the observed enrichments due to random chance.
- Compare to Bonferroni correction which is a bound on the probability that any one of the observed enrichments could be due to random chance.
- Typically FDR corrections are calculated using the Benjamini-Hochberg procedure.
- FDR threshold is often called the "q-value"



Benjamini-Hochberg example I

| Rank | Category | (Nominal) P-value |
|------|---|----------------------|
| 1 | Transcriptional | 0.001 |
| 2 | regulation | 0.002 |
| 3 | Transcription factor | 0.003 |
| 4 | Initiation of transcription | 0.0031 |
| 5 | Nuclear localization | 0.005 |
| | Chromatin modification | |
| 52 | | 0.97 |
| 53 | Cytoplasmic localization Translation | 0.99 |

Sort P-values of all tests in increasing order



Benjamini-Hochberg example II

| Rank | Category | (Nominal) P-value | Adjusted P-value |
|------|---|----------------------|------------------------------|
| 1 | Transcriptional | 0.001 | $0.001 \times 53/1 = 0.053$ |
| 2 | regulation | 0.002 | $0.002 \times 53/2 = 0.053$ |
| 3 | Transcription factor | 0.003 | $0.003 \times 53/3 = 0.053$ |
| 4 | Initiation of transcription | 0.0031 | $0.0031 \times 53/4 = 0.040$ |
| 5 | Nuclear localization | 0.005 | $0.005 \times 53/5 = 0.053$ |
| | Chromatin modification | | |
| 52 | | 0.97 | 0.985 x 53/52 = 1.004 |
| 53 | Cytoplasmic localization Translation | 0.99 | 0.99 x 53/53 = 0.99 |

Adjusted P-value is "nominal" P-value times # of tests divided by the rank of the P-value in sorted list Adjusted P-value = P-value X [# of tests] / Rank



Benjamini-Hochberg example III

| Rank | Category | (Nominal) P-value | Adjusted P-value | FDR / Q-value |
|------|---|----------------------|------------------------------|------------------|
| 1 | Transcriptional | 0.001 | $0.001 \times 53/1 = 0.053$ | 0.040 |
| 2 | regulation | 0.002 | $0.002 \times 53/2 = 0.053$ | 0.040 |
| 3 | Transcription factor | 0.003 | $0.003 \times 53/3 = 0.053$ | 0.040 |
| 4 | Initiation of transcription | 0.0031 | $0.0031 \times 53/4 = 0.040$ | 0.040 |
| 5 | Nuclear localization | 0.005 | $0.005 \times 53/5 = 0.053$ | 0.053 |
| | Chromatin modification | | | |
| 52 | | 0.97 | 0.985 x 53/52 = 1.004 | 0.99 |
| 53 | Cytoplasmic localization Translation | 0.99 | 0.99 x 53/53 = 0.99 | 0.99 |

Q-value (or FDR) corresponding to a nominal P-value is the smallest adjusted P-value assigned to P-values with the same or larger ranks.



Benjamini-Hochberg example III

| | P-value thresho | | 0.05 | FDR / |
|------|---|----------------------|------------------------------|---------|
| Rank | Category | (Nominal) P-value | Adjusted P-value | Q-value |
| 1 | Transcriptional | 0.001 | $0.001 \times 53/1 = 0.053$ | 0.040 |
| 2 | regulation | 0.002 | $0.002 \times 53/2 = 0.053$ | 0.040 |
| 3 | Transcription factor | 0.003 | $0.003 \times 53/3 = 0.053$ | 0.040 |
| 4 | Initiation of transcription | 0.0031 | $0.0031 \times 53/4 = 0.040$ | 0.040 |
| 5 | Nuclear localization | 0.005 | $0.005 \times 53/5 = 0.053$ | 0.053 |
| | Chromatin modification | | | |
| 52 | | 0.97 | 0.985 x 53/52 = 1.004 | 0 99 |
| - | Cutanlaamia laadization | •••• | | |
| 53 | Cytoplasmic localization Translation | 0.99 | 0.99 x 53/53 = 0.99 | 0.99 |

Red: non-significant Green: significant at FDR < 0.05

P-value threshold is highest ranking P-value for which corresponding Q-value is below desired significance threshold





Contents

2.1. What is Gene Set Analysis.
2.2. Before starting a Gene Set Analysis.
2.3. Gene Set Analysis --ORA
2.4. Gene Set Analysis --FCS
2.5. Multiple testing correction
2.6. Gene Set Analysis --Software



Where to find software?: Omicstools

| (i) ▲ https://omictools.com/search?q=pathway+analysis | |
|---|--|
| O PMIC TOOLS | pathway analysis Q • ? |
| SEARCH | |
| = FILTERS | < |
| SEARCH FOUND 341 RES | ESULTS FOR « PATHWAY ANALYSIS » |
| PLINK Desktop | PLINK ★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★ |
| PARIS Desktop | PARIS / Pathway Analysis by Randomization Incorporating Structure A A A A A A A (0) Image: 0 discussions Determines aggregated association signals generated from genome-wide association study results. Pathway-based analyses highlight biological pathways associated with phenotypes. PARIS uses a unique |
| SigMod | SigMod SigMod Market Constraints (GWAS) results and gene network to identify a strongly interconnected gene module enriched in high association signals. SigMod is formulated as a binary |



How to learn to use new software?

- 1. Try to find tutorials (or "vignettes" in R).
- 2. Read the manuals to see all other options that were not covered in the tutorials.
- 3. Ask questions. Don't be afraid to ask (but ask after you tried first).





GO





Gene Ontology Consortium

Search GO data

Search for terms and gene products...

Search

Ontology

Filter classes

Download ontology

Gene Ontology: the framework for the model of biology. The GO defines concepts/classes used to describe gene function, and

Annotations Download annotations (standard files) Eilter and download (sustamizable

Filter and download (customizable files <100k lines)

GO annotations: the model of biology. Annotations are statements describing the functions of specific The mission of the GO Consortium is to develop an up-to-date, comprehensive, **computational model of biological systems**, from the molecular level to larger pathways, cellular and organismlevel systems. more

Search documentation

arch

Q

What is the Gene Ontology?

An introduction to the Gene
 Ontology





111/11

128

百百日

DE DE

Same State

| | Homo sapiens (REF) | | | upload 1 (V Hiera | rchy_ | NEW! 🕏 | + |
|--|--------------------|----------|----------|-------------------|-------|-------------|----------|
| GO biological process complete | <u>#</u> | <u>#</u> | expected | Fold Enrichment | +/- | raw P value | FDR |
| endodermal cell fate specification | <u>6</u> | 2 | .00 | > 100 | + | 3.79E-07 | 9.95E-04 |
| ➡ <u>endodermal cell fate commitment</u> | <u>12</u> | 2 | .00 | > 100 | + | 1.23E-06 | 2.42E-03 |
| ➡ <u>endodermal cell differentiation</u> | <u>40</u> | 2 | .01 | > 100 | + | 1.17E-05 | 1.83E-02 |
| → <u>endoderm formation</u> | <u>46</u> | 2 | .01 | > 100 | + | 1.53E-05 | 2.18E-02 |
| ▶ <u>endoderm development</u> | <u>72</u> | 2 | .01 | > 100 | + | 3.65E-05 | 4.42E-02 |
| 4 formation of primary germ layer | <u>106</u> | 3 | .02 | > 100 | + | 1.35E-07 | 7.09E-04 |
| Lagastrulation | <u>152</u> | 3 | .02 | > 100 | + | 3.92E-07 | 8.81E-04 |
| + <u>embryonic morphogenesis</u> | <u>556</u> | 3 | .08 | 37.85 | + | 1.86E-05 | 2.44E-02 |
| Cell fate commitment involved in formation of primary germ layer | <u>26</u> | 3 | .00 | > 100 | + | 2.35E-09 | 3.70E-05 |
| ↓ <u>cell fate commitment</u> | <u>232</u> | 3 | .03 | 90.70 | + | 1.37E-06 | 2.40E-03 |
| ↓ <u>cell fate specification</u> | <u>73</u> | 2 | .01 | > 100 | + | 3.75E-05 | 4.22E-02 |
| somatic stem cell population maintenance | <u>53</u> | <u>3</u> | .01 | > 100 | + | 1.78E-08 | 1.40E-04 |
| → <u>stem cell population maintenance</u> | <u>124</u> | <u>3</u> | .02 | > 100 | + | 2.15E-07 | 8.44E-04 |
| haintenance of cell number | <u>127</u> | <u>3</u> | .02 | > 100 | + | 2.30E-07 | 7.25E-04 |



(i) A https://david.ncifcrf.gov







Gene List 💿 Background 🔵

Step 4: Submit List

Submit List



Annotation Summary Results

| Annotation Su | | ., | | Help and Too |
|--|---------------------------|------------|--------|----------------------------|
| Current Gene List | : List_2 | | | 4 DAVID IDs |
| Current Backgrou | ind: Hor | no | sapier | S Check Defaults Clear All |
| Disease (1 selected) | | | | |
| GAD_DISEASE | 100.0% | 4 | Chart | |
| GAD_DISEASE_CLASS | 100.0% | 4 | Chart | |
| MIM_DISEASE | 25.0% | 1 | Chart | |
| Functional_Catego | ories (3 s | elec | ted) | |
| | 25.0% | 1 | Chart | |
| | 100.0% | 4 | Chart | |
| | 100.0% | 4 | Chart | |
| | 100.0% | 4 | Chart | |
| Gene_Ontology (3 | selected) | | | |
| GOTERM_BP_1 | | 4 | Chart | |
| | 100.0% | 4 | Chart | |
| GOTERM_BP_2 | 100.0% | 4 | Chart | |
| _ | 100.0% | 4 | Chart | |
| GOTERM_BP_4 | 100.0% | 4 | Chart | |
| GOTERM_BP_5 | | | | |
| GOTERM_BP_ALL | 100.0% | 4 | Chart | |
| GOTERM_BP_DIRECT | 100.0% | 4 | Chart | |
| GOTERM_BP_FAT | 100.0% | 4 | Chart | |
| GOTERM_CC_1 | 100.0% | 4 | Chart | |
| GOTERM_CC_2 | 100.0% | 4 | Chart | |
| GOTERM_CC_3 | 100.0% | 4 | Chart | |
| GOTERM_CC_4 | 100.0% | 4 | Chart | |
| GOTERM_CC_5 | 100.0% | 4 | Chart | |
| GOTERM_CC_ALL | 100.0% | 4 | Chart | |
| GOTERM_CC_DIRECT | 100.0% | 4 | Chart | |
| GOTERM_CC_FAT | 100.0% | 4 | Chart | |
| GOTERM_MF_1 | 100.0% | 4 | Chart | |
| GOTERM_MF_2 | 100.0% | 4 | Chart | |
| GOTERM_MF_3 | 100.0% | 4 | Chart | |
| | 100.0% | 4 | Chart | |
| GOTERM_MF_4 | 100.0% | 4 | Chart | |
| | 100.0% | 4 | Chart | |
| GOTERM_MF_ALL | 100.0% | 4 | Chart | |
| | | | Chart | |
| GOTERM_MF_FAT | | | | |
| General_Annotation Literature (0 selected) | | ecte | ed) | |
| Main_Accessions (| |) | | |
| Pathways (1 selecte | | | | |
| KEGG_PATHWAY | 100.0% | 4 | Chart | |
| REACTOME_PATHWAY | 100.0% | 4 | Chart | |
| Protein_Domains | (2 selected | d) | | |
| REACTOME_PATHWAY Protein_Domains Protein_Interaction Tissue_Expression | (2 selecter ons (0 sel | d) ecte | | |

Results for KEGG Pathways



Functional Annotation Clustering

Current Gene List: List_2 Current Background: Homo sapiens 4 DAVID IDs Options Classification Stringency Medium ~ Rerun using options Create Sublist

1 Cluster(s)

<mark> Download File</mark>

Help and Manual

| | Annotation Cluster 1 | Enrichment Score: 2.4 | G | Count | P_Value | Benjamini |
|--|----------------------|---|-----------|-----------|---------|-----------|
| | GOTERM_BP_DIRECT | somatic stem cell population maintenance | <u>RT</u> | 4 | 5.5E-8 | 4.8E-6 |
| | GOTERM_BP_DIRECT | endodermal cell fate specification | <u>RT</u> | 3 | 2.1E-7 | 9.1E-6 |
| | KEGG_PATHWAY | Signaling pathways regulating pluripotency of stem cells | <u>RT</u> | 4 | 8.1E-6 | 2.4E-5 |
| | GOTERM_BP_DIRECT | regulation of gene expression | <u>RT</u> | 3 | 1.0E-4 | 3.0E-3 |
| | GOTERM_MF_DIRECT | transcription factor activity, sequence- specific DNA binding | <u>RT</u> | 4 | 1.8E-4 | 5.1E-3 |
| | GOTERM_BP_DIRECT | positive regulation of transcription from RNA polymerase II promoter | <u>RT</u> | 4 | 2.0E-4 | 4.3E-3 |
| | GOTERM_MF_DIRECT | transcription regulatory region DNA binding | <u>RT</u> | 3 | 4.7E-4 | 6.6E-3 |
| | UP_KEYWORDS | DNA-binding | <u>RT</u> | 4 | 9.9E-4 | 2.0E-2 |
| | UP_KEYWORDS | Transcription regulation | <u>RT</u> | 4 | 1.5E-3 | 1.4E-2 |
| | UP_KEYWORDS | Transcription | <u>RT</u> | 4 | 1.6E-3 | 1.0E-2 |
| | GOTERM_BP_DIRECT | transcription from RNA polymerase II promoter | <u>RT</u> | 3 | 2.7E-3 | 4.6E-2 |
| | GOTERM_MF_DIRECT | sequence-specific DNA binding | <u>RT</u> | 3 | 2.8E-3 | 2.5E-2 |
| | UP_KEYWORDS | Activator | <u>RT</u> | 3 | 3.0E-3 | 1.5E-2 |
| | GOTERM_CC_DIRECT | nucleoplasm | <u>RT</u> | 4 | 3.6E-3 | 3.2E-2 |
| | GOTERM_BP_DIRECT | negative regulation of transcription from RNA polymerase II promoter | <u>RT</u> | 3 | 5.4E-3 | 7.4E-2 |
| | UP_KEYWORDS | Developmental protein | <u>RT</u> | 3 | 6.2E-3 | 2.4E-2 |
| | UP_KEYWORDS | Isopeptide bond | <u>RT</u> | 3 | 8.7E-3 | 2.9E-2 |
| | UP_KEYWORDS | Nucleus | <u>RT</u> | 4 | 1.7E-2 | 4.7E-2 |
| | UP_KEYWORDS | Ubl conjugation | <u>RT</u> | 3 | 1.9E-2 | 4.8E-2 |
| | GOTERM_BP_DIRECT | regulation of transcription, DNA- templated | <u>RT</u> | 3 | 2.3E-2 | 2.5E-1 |
| | GOTERM_MF_DIRECT | DNA binding | <u>RT</u> | 3 | 2.8E-2 | 1.8E-1 |







Login | Register

13,432,841 lists analyzed 245,575 terms 132 libraries

Analyze

What's New? Libraries

About Help

Find a Gene

Input data

Choose an input file to upload. Either in BED format or a list of genes. For a quantitative set, add a comma and the level of membership of that gene. The membership level is a number between 0.0 and 1.0 to represent a weight for each gene, where the weight of 0.0 will completely discard the gene from the enrichment analysis and the weight of 1.0 is the maximum.

Try an example BED file.

Browse... No file selected.

Or paste in a list of gene symbols optionally followed by a comma and levels of membership. Try two examples: crisp set example, fuzzy set example



Enter a brief description for the list in case you want to share it. (Optional)



Contribute









P 10

目白日日

TT 10 TS





| 📌 Enrichr | | Login Register |
|--|--|---|
| Transcription Pathways Onto | logies Disease/Drugs Cell Typ | oes Misc Legacy Crowd |
| Description No description available (4 | 1 genes) | |
| Human Gene Atlas 🛛 🖯 | Mouse Gene Atlas 0 | ARCHS4 Tissues |
| PrefrontalCortex CD33+_Myeloid retina | embryonic_stem_line_V26_2_p16 embryonic_stem_line_Bruce4_p13 cornea | MORULA ESOPHAGUS (BULK TISSUE) AMNIOTIC FLUID |
| | stomach intestine_large | MIDBRAIN HUMAN EMBRYO |
| ARCHS4 Cell-lines 0 | Allen Brain Atlas up 🚯 | Allen Brain Atlas down 💿 |
| BXPC3 CFPAC1 | Sub paraventricular zone Bed nuclei of the stria terminalis, posterior c | mantle zone of r3Lim r6 alar plate |
| HCC1419 FADU | anteroventral periventricular preoptic nucle bed nucleus of the stria terminalis, mediose | intermediate stratum of r6Lim rhombomere 6 |
| T84 | bed nucleus of the stria terminalis, laterocer | rhombomere 7 |
| GTEx Tissue Sample Gene Expression | GTEx Tissue Sample Gene Expression | Cancer Cell Line 1 Encyclopedia |
| GTEX-NPJ8-0011-R7a-SM-2HMJV_brain_male GTEX-X261-0011-R5A-SM-3NMB4_brain_male | GTEX-TML8-0326-SM-4GICN_lung_female_40 GTEX-XUW1-2326-SM-4BOO5_breast_female | KYSE140_OESOPHAGUS TE6_OESOPHAGUS |
| GTEX-OHPN-0011-R7A-SM-215FI_brain_fema GTEX-TSE9-0011-R7A-SM-3DB7P_brain_fema | GTEX-R53T-1526-SM-48FEK_breast_female_5 GTEX-UJHI-0726-SM-3DB92_lung_female_50- | GOS3_CENTRAL_NERVOUS_SYSTEM |
| GTEX-PWO3-0011-R5A-SM-2I5EZ_brain_fema | GTEX-XUJ4-1426-SM-4BONT_lung_female_60 | HLC1_LUNG |



2 11:







2 11

14 14 14 13 13





| 🕨 🖹 😓 💺 🛔 🍕 🖆 🕑 | | 💽 ## · | 9) 🔘 | Enter search te | erm | 0 | - | H |
|---|-------------------------------|---|--------------|---|-----|-----------------------|-----|---|
| ntrol Panel | | | • 🗆 X | | | | | |
| vork Style Select Dynamic Network 🏶 ClueGO+CluePedia | | | | | | | | |
| | | | | | | | | |
| 9 | e | | <u> </u> | | | | | |
| ueGO Settings | | | | | | | | |
| Ontologies/Pathways 🕎 | Evidence 🕜 | | | | | | | |
| Type Name # Date Shape | Code | | | | | | | |
| GO BiologicalProcess-GOA 15 23.02.2017 Ellipse | All | | ~ | | | | | |
| GO CellularComponent-EBI-Qui 19 13.09.2017 Ellipse | All_Experimental_(EXP,IDA,I | PI,IMP,IGI,IEP) | | | | | | |
| GO CellularComponent-GOA 18 23.02.2017 Ellipse | All_without_IEA | | | | | | | |
| GO ImmuneSystemProcess-EB 11 13.09.2017 Dilpse | EXP (Inferred from Experime | | | | | | | |
| 00 MalagularEurotias EBI Quia 48, 12 09 2017 | IBA (Inferred from Biological | | | | | | | |
| GO Molecular-uncluin-con-colo4013.03.2017 Emple | IBD (Inferred from Biological | Aspect of Descende | ~ | | | | | |
| - Update Ontologies | 4 | | 0 | | | | | |
| Update Ontologies, Pathways & Annotation Files | | | | | | | | |
| REACTOME - Update REACTOME pathways/reactions | | ~ | | | | | | |
| ClueGO Update | | | | | | <u></u> | | |
| | | Update | | | | | | |
| Network Specificity | | Detailed | 0 | | | | | |
| Coold Medun Use GO Term Fusion @ Medun Show only Pathways with pV s Advanced Term/Pathway Selection Options | | | | | | | | |
| • | | Detailed | | III C Network | | 2 0-0 4 | 0-0 | ¢ |
| Owner Network: Specificity Owner Medium Use GO Term Fusion Image: Content of the second seco | | Detailed 0.0500 | • • | Table Panel | | 2 0-0 Ø | | • |
| Bood Metwork: Specificity Use GO Term Fusion Image: Control of the second seco | | Detailed 0.0000 V Max Lavel | | Table Panel | | 2 0-0 Ø | | • |
| Occod Metwork Specificity Use GO Term Fusion Image: Comparison of the second s | | Detailed 0.0500 | | Table Panel | | 2 0-0 Ø | | • |
| Octor Metwork Specificity Use GO Term Fusion Image: Control of the second sec | | Detailed 0.0000 V Max Lavel | | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 4 | | • |
| Good Metwork: Specificity Use GO Term Fusion Image: Control of the second seco | | Detailed 0.0000 V Max Lavel | •• | Table Panel | | 2 0-0 Ø | | • |
| October Metwork Specificity Use GO Term Fusion Image: Control of the c | 60 ∳i is Specific | Detailes 0.0000 ✓ Max Lavel (4.000 (♦) %Ger | •• | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 4 | | • |
| Good Metwork: Specificity Use GO Term Fusion Image: Constraint of the second s | | Detailes 0.0000 ✓ Max Lavel (4.000 (♦) %Ger | •• | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 Ø | | • |
| Orioli Motion Use 60 Tem Fusion Image: Constraint of the second | | Detailes 0.0000 ✓ Max Lavel (4.000 (♦) %Ger | •• | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 ∳Ø | | • |
| Good Metwork: Specificity Use GO Term Fusion Image: Constraint of the second s | | Detailes 0.0000 ✓ Max Lavel (4.000 (♦) %Ger | •• | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 4 | | • |
| Bobal Metwork: Specificity Use GO Term Fusion Image: Constraint of the second | 00]∰% is Specific | Detailes 0.0000 ✓ Max Lavel (4.000 (♦) %Ger | •• | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 4 | | • |
| Good Metwork Specificity Use Of Term Fusion Image: Control of the second secon | 00]∰% is Specific | Detailed 0.000 Max Level 4.000 🔄 %Ger | •• | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 4 | | • |
| Octor Metwork Specificity Use GO Term Fusion Image: Control of the second seco | 00]∰% is Specific | Detailed 0.000 Max Level 4.000 🔄 %Ger | •• | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 Ø | | • |
| Bood Metwork Specificity Use GO Term Fusion Image: Control of the second secon | 00]∰% is Specific | Detailed 0.000 Max Level 4.000 🔄 %Ger | 5 5 6 | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 Ø | | |
| Groud Medium Use Go Term Fusion Image: Comparison of the second seco | 00[∳]% is Specific H | Destries 0.0000 ↓ Max Level (4.000 ◆ %Ger 4.000 ◆ %Ger 4.000 ◆ %Ger | 5 5 6 | Table Panel \clubsuit \square $+$ \square $\blacksquare f(x)$ | | 2 0-0 9 | | • |

















Enrichment Map







- Use available gene-set scoring models
 - threshold dependent (e.g. Fisher's) or threshold free (e.g. GSEA)
- Use the network framework to organize gene-sets exploiting their inter-dependencies

http://baderlab.org/Software/EnrichmentMap/





Pathway enrichment analysis software: R / Bioconductor



ORA: topGO, clusterProfiler, RDAVIDWebService, ReactomePA, enrichR, GOseq, PathwaySplice

FCS: globaltest, gage, Camera, PADOG, SetRank

Others: GSVA, SPIA, PathNet, TcGSA, QuSAGE, DNEA

Ensembles: piano, EGSEA, ToPASeq... And many more





Final remarks:



- You can always find standalone and web-based applications for pathway analysis, but many tools exist either as scripts or as libraries that you must run.
- Therefore, it is good to learn how to program.
- Currently, the two most popular programming languages in bioinformatics are R and python. R has a suite of software for bioinformatics called "Bioconductor", while python has "bioconda".
- Learn R!





What have we learned today?

What is pathway/gene-set analysis How to perform gene set analysis Two types of gene set analysis (ORA and FCS) What is multiple test correction How to use software for gene set analysis (ORA and FCS)

